BAT 25bn Write-Down|Smoke-Free Pivot at Risk?

The £25bn Question

British American Tobacco took a £25 billion impairment charge this week — primarily against its US cigarette brands — and the share price fell more than 3 per cent on the day. The surface reading was straightforward: cigarette volumes declining faster than forecast, the write-down was overdue. But the decline itself was not the question the market was actually pricing. What the sell-off exposed was something more structurally uncomfortable — whether the smoke-free pivot can carry the valuation weight that the legacy combustibles business is steadily surrendering.

BAT's new categories division, led by nicotine pouches and vapes, delivered revenue growth in the mid-teens percentage range. Velo and Vuse both showed momentum. The full-year revenue guidance held — 3 to 5 per cent growth, profits 4 to 6 per cent up — and a £1.3 billion buyback remains on track. None of that prevented the share price from falling. That gap between affirmed guidance and equity re-rating is the real signal. Income-focused holders, who built positions on the assumption that legacy tobacco cash flows would finance the transition, are now recalibrating how long that bridge holds.

Global cigarette volumes are expected to fall 2.5 per cent this year, accelerating from a prior 2 per cent forecast. The US market, where BAT had 83 per cent of group revenues still coming from combustibles, is at the centre of that acceleration. CDC survey data showed adult smoking at an all-time low — one in nine adults — against 42 per cent in the 1960s. That structural fact was not news. What was news is that the write-down formally locked in the timeline: BAT can no longer treat its combustibles book as a stable cash-generating base while the smoke-free transition matures at its own pace. The impairment forces the question into the present. The residue the market is now sitting with is whether mid-teens revenue growth in new categories, currently 18 per cent of group revenues, can reach the 50-per-cent-by-2035 target fast enough to offset what is being written off today — and at what cost to the dividend that makes the FTSE 100 income case.

The Margin Environment

BAT's internal timeline pressure does not exist in isolation, and that is what the second layer of this repricing adds. The external cost environment facing UK businesses this quarter arrived from two directions at once — and both of them compress the margin logic that underpins BAT's transition case.

Marks and Spencer's chairman stated this week that Britain had "rarely in the history" of the retailer been "less friendly to growth and investment." That is not a BAT-specific comment, but the mechanism it describes reaches BAT's pricing structure directly. National Insurance contribution increases took effect last April. Minimum wage rises for the 18-to-20 cohort ran 8.5 per cent. Business rates increased simultaneously. These are domestic, labour-law-origin cost pressures that flow through to every consumer-facing business in the UK — including the vaping retail channel through which BAT distributes its new categories products.

Now layered on top is the Iran war's transmission into UK energy costs. Rachel Reeves' budget headroom — estimated at £24 billion as recently as March — is now being revised downward by the OBR, which acknowledged it underestimated the second-round effects of the 2022 energy shock and will apply the same analytical frame to the current disruption. Oil inventories are at critical levels ahead of peak summer demand. The Bank of England has flagged a potential peak of 4 per cent inflation this summer, with a severe scenario reaching 6 per cent by early 2027. That is not a floor-price problem for BAT's nicotine pouches — pouches are priced at a premium to cigarettes and carry strong margin. The problem is that the consumer sitting at the other end of that purchase is facing a cost squeeze that makes discretionary spending in any category less predictable.

The shared frame here is not sector rotation or a thematic trade. It is the income-stock thesis under compression — specifically, whether the FTSE 100 dividend yield argument for BAT holds when the transition timeline is lengthening, the domestic cost base is rising, and the energy shock removes the macro stability that FTSE income allocators use to underwrite steady payouts. Institutional flows into BAT year-to-date have tracked the dividend re-rating cycle; the 3.1 per cent share price decline on the guidance day — not a guidance cut day, an affirmed guidance day — suggests those flows are reassessing their residual exposure rather than adding on weakness.

The Verification Point

The case for holding BAT through this repricing rests on one arithmetic question: does the smoke-free revenue growth rate compound fast enough, between now and 2035, to replace what the US combustibles impairment has formally written off? The company says it does. The market, on an affirmed-guidance day, said it is not yet priced to believe that. That divergence between management signalling and equity market response is the operational centre of the repricing.

The specific number to track is the new categories revenue share. It stands at 18 per cent of group revenues. The 2035 target is 50 per cent. That requires compounding from 18 to 50 — across a base still predominantly weighted to cigarettes — over nine years, while global cigarette volumes decline at an accelerating rate and the UK cost environment adds friction to every sales channel below the premium tier. Mid-teens percentage growth in new categories, sustained, achieves that path. The question is whether mid-teens is sustainable once UK consumer income is under sustained pressure from both policy-side costs and an energy shock that the OBR has explicitly said will feed into its next forecast.

The verification benchmark is the ECB decision on 11 June and the OBR's updated UK fiscal forecast expected in the back half of this year. Neither of those is a BAT-specific event. Both will reset the macro cost frame inside which the dividend-yield argument either holds or is revised further. BAT's dividend is not under immediate threat — the buyback is on track and full-year guidance is affirmed. The thesis weakens not if BAT cuts the dividend, but if the income-stock allocation frame for FTSE 100 defensives broadly narrows, leaving BAT competing for yield-seeking capital in an environment where other asset classes are repricing upward. That is the condition to monitor: whether FTSE 100 income-stock flows remain net positive for BAT through the summer, or whether the energy-driven inflation reset reallocates capital out of the defensive yield frame entirely.